Updated: 17th December 2024
The Follicular Lymphoma Foundation (FLF) was thrilled to participate in the recent American Society of Hematology (ASH) Annual Meeting, a premier event uniting top experts in hematology to share innovative research and medical advancements. This year’s conference in San Diego, US, offered an essential opportunity for the FLF to further our mission of unlocking a cure for follicular lymphoma.
We’re preparing a detailed summary of these advancements and what they mean for the future of FL treatment, which we’ll share with you soon.
Our presence at ASH reflects our unwavering dedication to ensuring patients remain central to conversations about follicular lymphoma. By engaging directly with scientists, researchers, and pharmaceutical leaders, we work to prioritize follicular lymphoma on the global research agenda. Our aim is to emphasize the urgency of developing more effective, patient-focused treatments while advancing the search for a cure.
Through collaboration and partnerships, the FLF amplifies the voices of those living with follicular lymphoma. We are committed to ensuring their needs not only shape the conversation but also drive innovation in research and treatment.
Patient-centered research is the cornerstone of our participation in ASH. We believe breakthroughs in treatment must be informed by the needs of those affected, and we actively collaborate with leading researchers and clinicians to integrate patient perspectives into the research process.
Insights from our patient surveys played a pivotal role in shaping our contributions at ASH, highlighting the challenges patients face and guiding improvements in care for both researchers and healthcare providers.
ASH offers a unique platform for the FLF to connect with the global scientific community, identify breakthrough research, and accelerate the development of innovative treatments. Through in-depth discussions, we aim to strengthen existing partnerships and forge new collaborations that support critical initiatives like our Biomarker Discovery Program and CURE FL Awards. These efforts are vital for expediting new treatments and improving outcomes for patients.
At ASH, the FLF remained focused on ensuring that follicular lymphoma received the attention it deserves. The insights and partnerships gained during the conference will play a crucial role in shaping the future of research, bringing us closer to achieving our ultimate goal: a cure for follicular lymphoma.
Help us drive life-changing research for follicular lymphoma patients. Your donation directly supports our efforts to advance innovative treatments and bring us closer to a cure.
